A Real-World Study Investigating Maintenance Rituximab after First Line Induction Therapy in Patients with Follicular Lymphoma treated at the Veterans Health Administration (VHA)

Trial Profile

A Real-World Study Investigating Maintenance Rituximab after First Line Induction Therapy in Patients with Follicular Lymphoma treated at the Veterans Health Administration (VHA)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Dec 2017 New trial record
    • 12 Dec 2017 According to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology, the end date of study observation period is 31 Dec 2016.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top